This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
At Pfizer Oncology Together, patient support is at the core of everything we do. We’ve gathered resources and developed tools to help patients and their loved ones throughout BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) treatment. From helping to identify financial assistance options to connecting patients to resources for emotional support, our patients’ needs are our priority.
Pfizer Oncology Together is committed to supporting patients as they navigate access to prescribed Pfizer Oncology medications. We offer tools and resources to help patients receive their prescribed BRAFTOVI + MEKTOVI in a timely manner, including benefits verification and information related to prior authorizations, appeals, product distribution, and billing and coding.
Pfizer Oncology Together can help patients understand their insurance benefits and connect them with financial assistance resources (if needed), regardless of their insurance coverage.
Help identifying resources for patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans who express a financial need:
Help identifying resources for patients without any form of healthcare coverage who may be eligible:
Help identifying resources for patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans who express a financial need and may be eligible:
Help identifying resources for patients without any form of healthcare coverage who may be eligible:
Help identifying resources for patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans who express a financial need and may be eligible:
Help identifying resources for patients without any form of healthcare coverage who may be eligible:
When patients and caregivers need support for their day-to-day challenges with treatment, we want to be a place they can turn to for help. At Pfizer Oncology Together, our Care Champions, who have social work experience, can connect patients prescribed BRAFTOVI + MEKTOVI to resources that may help with some of their daily needs.§
§Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.
When patients and caregivers need support for their day-to-day challenges with treatment, we want to be a place they can turn to for help. At Pfizer Oncology Together, our Care Champions, who have social work experience, can connect patients prescribed BRAFTOVI + MEKTOVI to resources that may help with some of their daily needs.§
We can connnect patients to diagnosis-specific support groups, an independent organization that offers short-term counseling, and a free app, developed by Pfizer Oncology, to help patients connect with loved ones and ask for the support they need.
To help support patients’ mental well-being and physical health, we’ve created resources on topics like nutrition, stress management, and communication.
If patients need assistance with transportation or lodging for treatment-related appointments, we’ll connect them to independent organizations that offer these services for free to qualifying patients.
This Is Living With Cancer™ is a free online resource developed by Pfizer Oncology for all people living with cancer, regardless of age, income, race, location, cancer type, or stage of disease. This comprehensive program is available to anyone in the United States, whether they are on a Pfizer treatment or not, with a growing focus on those facing challenges accessing care.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
PP-BMK-USA-0786
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) are kinase inhibitors indicated for use in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.